Business Description
4basebio PLC
ISIN : GB00BMCLYF79
Share Class Description:
XTER:88Q: Ordinary SharesTotal Employee Number:
140Description
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.07 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 1.65 | |||||
Debt-to-EBITDA | -1.07 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -1.21 | |||||
Beneish M-Score | -2 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 70.5 | |||||
3-Year EBITDA Growth Rate | -31.8 | |||||
3-Year EPS without NRI Growth Rate | -37.4 | |||||
3-Year FCF Growth Rate | -27.3 | |||||
3-Year Book Growth Rate | 4.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 42.87 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 159.41 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 4.28 | |||||
9-Day RSI | 24.91 | |||||
14-Day RSI | 39.08 | |||||
3-1 Month Momentum % | 13.27 | |||||
6-1 Month Momentum % | -8.57 | |||||
12-1 Month Momentum % | -42.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.31 | |||||
Quick Ratio | 7.07 | |||||
Cash Ratio | 6.3 | |||||
Days Inventory | 263.98 | |||||
Days Sales Outstanding | 49.23 | |||||
Days Payable | 616.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.9 | |||||
Shareholder Yield % | -1.89 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 57.53 | |||||
Operating Margin % | -984.29 | |||||
Net Margin % | -998.52 | |||||
EBITDA Margin % | -919.73 | |||||
FCF Margin % | -1012.51 | |||||
OCF Margin % | -916.51 | |||||
ROE % | -91.42 | |||||
ROA % | -45.63 | |||||
ROIC % | -160.21 | |||||
3-Year ROIIC % | -288.05 | |||||
ROC (Joel Greenblatt) % | -386.68 | |||||
ROCE % | -48.91 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 48.17 | |||||
PB Ratio | 8.04 | |||||
Price-to-Tangible-Book | 15.53 | |||||
EV-to-EBIT | -4.8 | |||||
EV-to-Forward-EBIT | -5 | |||||
EV-to-EBITDA | -5.15 | |||||
EV-to-Forward-EBITDA | -5.49 | |||||
EV-to-Revenue | 47.38 | |||||
EV-to-Forward-Revenue | 28.65 | |||||
EV-to-FCF | -4.66 | |||||
Price-to-GF-Value | 0.18 | |||||
| Price-to-Net-Current-Asset-Value | 65.56 | |||||
Earnings Yield (Greenblatt) % | -20.83 | |||||
FCF Yield % | -21.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
4basebio PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.974 | ||
| EPS (TTM) (€) | -1.263 | ||
| Beta | 0.7281 | ||
| 3-Year Sharpe Ratio | 0.01 | ||
| 3-Year Sortino Ratio | 0.02 | ||
| Volatility % | 39.63 | ||
| 14-Day RSI | 39.08 | ||
| 14-Day ATR (€) | 0.055544 | ||
| 20-Day SMA (€) | 6.15 | ||
| 12-1 Month Momentum % | -42.86 | ||
| 52-Week Range (€) | 4.64 - 11.5 | ||
| Shares Outstanding (Mil) | 15.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
4basebio PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
4basebio PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-09-29 | In 79 days | ||
| General meeting for 2025 | 2026-06-30 09:00 | 5.90 (+0.00%) | ||
| Annual report for 2025 | 2026-06-08 | 6.40 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-05-20 | 4.80 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-29 | 8.00 (+0.00%) | ||
| General meeting for 2024 | 2025-06-27 09:00 | 11.50 (+1.77%) | ||
| Annual report for 2024 | 2025-05-30 | 13.20 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-05-27 | 13.20 (+0.76%) | ||
| Second quarter earnings results for 2024 | 2024-09-27 | 16.90 (+1.20%) |
Show
Entries
4basebio PLC Frequently Asked Questions
What is 4basebio PLC(XTER:88Q)'s stock price today?
The current price of XTER:88Q is €5.90. The 52 week high of XTER:88Q is €11.50 and 52 week low is €4.64.
When is next earnings date of 4basebio PLC(XTER:88Q)?
The next earnings date of 4basebio PLC(XTER:88Q) is 2026-09-29 Est..
Does 4basebio PLC(XTER:88Q) pay dividends? If so, how much?
4basebio PLC(XTER:88Q) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| 4basebio Introduces New Branding to Reflect Next Phase of Growth Enabling Development of Advanced Genetic Therapies | 2025-07-01 |
Articles on 4basebio PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers